Compounded Tirzepatide vs Zepbound: Cost and Differences

Compounded tirzepatide is often advertised at prices below brand-name Zepbound, but the price gap is much smaller than it used to be, and the money saved comes with a trade-off in oversight. Through Lilly’s self-pay program, Zepbound starts at $299 a month at the 2.5 mg starting dose, $399 at 5 mg, and $449 at all higher doses if refilled within 45 days, with eligibility required and terms and conditions applying ^[3]. Compounded tirzepatide was reported selling for as little as $99 a month in 2025, when Zepbound’s sticker price was more than $1,086.37 a month ^[1]. Today’s advertised compounded prices vary widely and there is no manufacturer-published price to check them against, so any figure is provider- or directory-reported and unaudited.

The other difference matters just as much as price. Zepbound is FDA-approved and reviewed for safety, effectiveness, and quality before marketing. Compounded drugs are not — FDA does not review them before they reach patients ^[2]. FDA has documented potency and sterility failures at compounding pharmacies in warning letters ^[7][8], and Lilly has reported finding an impurity in compounded tirzepatide-B12 products based on its own testing ^[6].

What is compounded tirzepatide, and why isn’t it a generic?

Tirzepatide is the active ingredient in Lilly’s Zepbound, approved for weight loss, and Mounjaro, approved for type 2 diabetes ^[1][6]. Lilly makes the only FDA-approved tirzepatide product, according to allegations in Lilly’s own complaint reported by NPR ^[1].

Compounded drugs are not generics. They are essentially copies that special pharmacies called compounding pharmacies were permitted to make during drug shortages ^[1]. Compounded GLP-1s are often inaccurately described as “generic” versions of semaglutide or tirzepatide, according to the Connecticut attorney general ^[4].

The practical difference: a generic drug goes through an FDA approval process. A compounded drug does not. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed ^[2]. Compounded GLP-1s are also often dispensed in multi-dose vials that patients draw from themselves with syringes, rather than single-dose pens ^[2].

What does Zepbound cost out of pocket in 2026?

LillyDirect lists self-pay prices by dose. A “month” is defined as 28 days — either 4 single-dose vials or 1 single-patient-use KwikPen ^[3].

Dose	Self-pay price	Regular price if not refilled within 45 days
2.5 mg (starting dose)	Starting at $299/month	—
5 mg	Starting at $399/month	—
7.5 mg	$449/month	$499
10 mg	$449/month	$699
12.5 mg	$449/month	$699
15 mg	$449/month	$699

The $449 price at 7.5 mg and above reflects the Zepbound Journey Program and requires refilling within 45 days ^[3]. The 2.5 mg dose is a starting dose only and is not approved as a maintenance dose ^[3].

A few things to know about these prices:

• The self-pay program requires eligibility, is not insurance, and savings are subject to monthly and annual limits. Lilly can amend or terminate the program at any time without notice ^[3].
• Pen needles for the KwikPen, or needles and syringes for the vial, are purchased separately — they are not included in the listed prices ^[3].
• Zepbound comes in three formats: a single-dose vial (LillyDirect self-pay only), a single-dose pen (insurance accepted), and a KwikPen (self-pay plus select insurance) ^[3].
• With insurance, the single-dose pen can cost as low as $25 a month for up to a 3-month prescription, with terms and conditions ^[3].
• Eligible Medicare Part D patients with a Zepbound KwikPen prescription for weight management can access the drug through the Medicare GLP-1 Bridge program ^[3].

What does compounded tirzepatide cost, and why are advertised prices unreliable?

In 2025 reporting, compounded tirzepatide sold for as little as $99 a month ^[1]. But there is no manufacturer-published price for compounded tirzepatide. Every figure comes from a provider’s website or a price directory, and none of it is audited. Advertised prices function as quotes from individual sellers, not as a market rate.

Several common pricing structures can make compounded drugs look cheaper than they are:

• A separate monthly membership or consultation fee charged on top of the medication price.
• Dose-tier pricing that rises as the dose is titrated up, so the advertised price applies only to the lowest dose.
• Prepaid multi-month plans quoted as a low monthly rate.
• 28-day billing cycles, which work out to 13 charges a year rather than 12.

A like-for-like comparison uses the all-in 12-month total at the expected maintenance dose, with membership fees included. FDA also lists “prices that seem too good to be true” as a telehealth red flag ^[2].

Lilly has taken sellers to court over these products. On April 23, 2025, Lilly sued telehealth firms Mochi Health, Willow Health, Fella Health and Delilah, and Henry Meds, after earlier suits against compounders Strive and Empower on April 1, 2025 ^[1].

Is what’s in the vial the same as Zepbound?

Not necessarily. Several documented differences go beyond the label:

Salt forms. FDA has stated that salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate, are different active ingredients than those used in the approved drugs, and the agency is not aware of any lawful basis for their use in compounding ^[2]. A May 21, 2025 notice from the Connecticut attorney general cited compounders’ use of salt forms of semaglutide and/or tirzepatide, many sourced from overseas manufacturers with spotty inspection records ^[4].

Overseas sourcing. Data cited by the Connecticut attorney general from Brookings found that three Chinese firms responsible for 20% of reported imported semaglutide volume had never been inspected as of September 2024, and three more firms responsible for 44.5% of imported volume had been cited for current good manufacturing practice violations ^[4].

Additives. A secret-shopper study published in JAMA Health Forum, covering 75 businesses in two states between August and October 2025, found that 44 businesses (58.7%) offered compounded GLP-1s with some additive, 42 (56.0%) offered B vitamins, 5 (6.7%) offered levocarnitine, and 4 (5.3%) offered glycine ^[5]. Tirzepatide was offered by 65 businesses (86.7%), and 7 (9.3%) offered oral formulations ^[5]. No FDA-approved semaglutide or tirzepatide injection contains vitamin additives, and there are no clinical trials of such combinations ^[4].

Impurities. In a public letter dated March 12, 2026, Lilly reported that its own testing of samples obtained from compounding pharmacies, medspas, and telehealth networks found significant levels of an impurity caused by a chemical reaction between tirzepatide and B12 in all 10 compounded samples tested, and the company called for a nationwide recall of products containing both ingredients ^[6]. Scott Brunner, CEO of the Alliance for Pharmacy Compounding, called the findings concerning but said Lilly had not disclosed enough detail about its sampling process to fully assess the risk to consumers ^[6].

Potency and sterility failures. An FDA warning letter dated January 16, 2026, covering an inspection of a Kennett Square, Pennsylvania pharmacy from May 12 to June 9, 2025, found Tirzepatide 10 mg/mL lots at 86.8% and 89.1% of labeled potency that were distributed anyway, semaglutide 2.5 mg/mL at 79.9% potency, and a lot combining tirzepatide, glycine, and methylcobalamin that failed sterility testing and was still distributed ^[7]. Of 23 out-of-specification investigations reviewed from November 2024 to May 2025, none followed the firm’s own procedures, none documented contacting affected patients, and 19 remained open ^[7].

Facility quality. In the JAMA study, of 23 facilities identified as suppliers, 17 of 21 were licensed for sterile compounding, 4 lacked sterile licensure, 4 had faced disciplinary action since 2023, and 3 had open FDA Form 483s ^[5]. Separately, ProRx LLC, a registered 503B outsourcing facility, initiated a voluntary recall on October 15, 2025 of a tirzepatide 27 mg/3 mL multi-dose vial lot and semaglutide multi-dose lots for lack of sterility assurance, and received an FDA warning letter on April 7, 2026 ^[8].

FDA also advises patients to discard multi-dose sterile vials within 28 days of first use even if medication remains, to use a new sterile needle and syringe for each dose, and not to use any injectable GLP-1 that arrives warm or with insufficient refrigeration ^[2].

Do compounded versions produce the same weight loss as the Zepbound trials?

There is no way to know from the evidence available, and claiming equivalence is itself a red flag. FDA has issued warning letters to 30 telehealth companies for false or misleading claims about compounded weight-loss drugs ^[6][9][10]. One of FDA’s consumer red flags is a company claiming its compounded drug is the same as an FDA-approved drug ^[2].

Lilly’s lawsuits allege examples of this marketing. The complaint against Henry Meds alleges the company improperly referenced Lilly’s approved drugs and clinical trials on its website to sell compounded versions. The complaint against Fella alleges the company told patients its untested oral drug is better than Lilly’s approved medicines. The complaint against Willow alleges the company falsely claimed to have developed the first “cosmetic” GLP-1 ^[1].

FDA has approved GLP-1 medications only for chronic weight management in adults with obesity, or overweight plus a weight-related comorbidity such as hypertension or type 2 diabetes — not for cosmetic purposes ^[4]. Trial results for Zepbound apply to the FDA-approved product that was tested, not to untested copies.

How many safety complaints has FDA received about compounded tirzepatide?

As of May 31, 2026, FDA had received more than 730 adverse event reports for compounded tirzepatide and 990 for compounded semaglutide ^[2][11]. Underreporting is likely, because federal law does not require state-licensed pharmacies that are not outsourcing facilities to report adverse events to FDA ^[2].

Many of the reported events appear consistent with those seen with the FDA-approved versions ^[2]. But FDA has also received reports of dosing errors, some requiring hospitalization, from patients measuring and self-administering incorrect doses and from clinicians miscalculating doses. Additional adverse events have been reported with doses beyond the approved label — larger doses, more frequent dosing, or faster titration — including nausea, vomiting, diarrhea, abdominal pain, and constipation ^[2].

FDA is also aware of fraudulent compounded semaglutide and tirzepatide with false label information. In some cases, the pharmacies named on labels do not exist; in others, the label names a licensed pharmacy that did not make the product. One adverse event report tied to a product labeled as compounded tirzepatide from a pharmacy that did not compound it included redness, swelling, pain, and a red lump at the injection site ^[2]. FDA has also established a green list import alert (66-80) to stop GLP-1 active pharmaceutical ingredients with potential quality concerns at the border ^[2].

Is compounded tirzepatide still legal now that the shortage ended?

That is the central legal fight. Tirzepatide was in shortage for two years until December 19, 2024. FDA required an end to making copies by mid-March 2025, though pharmacies could sell already-produced stock until it ran out or expired ^[1]. Compounding pharmacies are no longer allowed to manufacture semaglutide or tirzepatide weight-loss injections in bulk because these drugs are off the FDA shortage list ^[4].

Federal law prohibits compounders from making what is essentially a copy of a commercially available drug ^[1]. Compounders argue a narrow provision of federal law permits compounding when patients need personalization for medical reasons, such as added vitamins or doses not available in the branded versions ^[6].

For 503B outsourcing facilities, the exemptions require that the bulk substance be on the 503B bulks list or that the drug be on the shortage list at the time of compounding ^[8]. FDA has pursued this route: ProRx was cited in its warning letter for compounding with tirzepatide bulk drug substance ^[8]. How the courts and regulators ultimately resolve the question remains open, and the fight is currently playing out through FDA warning letters, recalls, and Lilly’s lawsuits ^[1][6][8].

Side-by-side: compounded tirzepatide vs Zepbound

	Zepbound	Compounded tirzepatide
FDA-approved	Yes [2]	No [2]
Cash price	Starting at $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg with 45-day refill); $499–$699 regular at higher doses [3]	No published list price; reported as low as $99/month in 2025 [1]
Device	Single-dose vial, single-dose pen, or KwikPen [3]	Typically multi-dose vial plus separate syringes [2]
Quality testing	FDA-reviewed before marketing [2]	Depends on the individual pharmacy, with documented potency and sterility failures [5][7][8]

How do you evaluate a compounded program before paying?

FDA’s advice is to use compounded drugs only when a patient’s medical needs cannot be met by an FDA-approved drug, to get a prescription from a doctor, and to fill it at a state-licensed pharmacy ^[2].

FDA’s telehealth red flags include: no screening or prescription by a licensed doctor, no doctor available to answer questions afterward, spelling errors on the label or incorrect pharmacy addresses, damaged packaging, and product that looks different from what was received before ^[2].

Questions worth asking a seller, drawn from FDA guidance and the study findings:

• The compounder’s legal name, state, sterile-compounding license, and whether it is a 503A pharmacy or a 503B outsourcing facility — information that can be checked with the state board of pharmacy ^[5][8].
• Whether the active ingredient is tirzepatide base or a salt form, and what additives are included and why ^[2][4][5].

FDA’s BeSafeRx resource covers how to buy prescription medicines online safely ^[2].

The bottom line: the cost gap narrowed, the oversight gap did not

During the shortage, the choice was stark: compounded tirzepatide at as little as $99 a month versus Zepbound’s sticker price of more than $1,086.37 a month ^[1]. Now Zepbound self-pay starts at $299 to $449 a month ^[3], so the savings from compounded versions are smaller than advertised prices suggest once memberships, dose tiers, and 28-day billing cycles are counted.

What has not changed is oversight. The approved product was reviewed before marketing; the compounded product was not ^[2]. FDA advises that compounded drugs be used only when a patient’s medical needs cannot be met by an FDA-approved drug, and encourages patients to talk with their health care provider about their medicines ^[2].

Sources

1. NPR. Eli Lilly sues companies selling alternative versions of its weight loss drug. April 23, 2025.
2. US Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
3. Eli Lilly and Company. Zepbound (tirzepatide) shipped to you through LillyDirect.
4. Connecticut Office of the Attorney General. Letter to weight loss clinics and spas re: compounded GLP-1 weight loss medications. May 21, 2025.
5. JAMA Health Forum. Postshortage compounded GLP-1 RA market in 2 states with potentially high demand.
6. Reuters. Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks. March 12, 2026.
7. The FDA Group Insider. FDA warning letter breakdown: sterility failures, subpotent GLP-1 drugs, and a compounding pharmacy operating without control.
8. US Food and Drug Administration. Warning letter to ProRx LLC. April 7, 2026.
9. US Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s.
10. Foley & Lardner LLP. GLP-1 compliance: FDA targets telehealth marketing in 30 new warning letters. March 12, 2026.
11. Becker’s Hospital Review. FDA warns on compounded GLP-1s amid 1,700+ safety reports. September 8, 2026.
12. Medicare.gov. Weight loss drugs.
13. US Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA, No. 25-10600. August 27, 2026.